Wallace M/LinkedIn
Jan 3, 2026, 14:08
Wallace M Shares a SWOT Analysis of Aqvesme’s FDA Approval
Wallace M, CEO and Founder of i3consult.com, shared on LinkedIn:
”FDA APPROVAL UPDATE: Aqvesme™ (mitapivat) for Thalassemia‑Related Anemia
The FDA approval of Aqvesme™ introduces the first oral, disease‑modifying therapy for anemia in adults with alpha‑ or beta‑thalassemia.
Our latest SWOT analysis explores the clinical significance and strategic implications of this milestone.
Read the full analysis.”
Stay updated with Hemostasis Today.
-
May 19, 2026, 08:52Konstantin Stark: Announcing the Launch of Collaborative Research Center 1784 to Advance Thromboinflammation Research
-
May 19, 2026, 08:35Gokhan Ozdemir: Managing Acute Flow Diverter Stent Thrombosis in a Critical Vertebrobasilar Circulation
-
May 19, 2026, 08:28Rashad Falah: Evaluating Long Term Outcomes and Transfusion Risks in Obscure Gastrointestinal Bleeding
-
May 18, 2026, 16:35Abdurrahmaan Ali Suei Elbuzidi: What is the Optimal Anticoagulation Monitoring Target in ECMO?
-
May 18, 2026, 16:34Serah N. Gathu: Gaining Valuable Updates on ACS Management at the Africa STEMI Conference
-
May 18, 2026, 16:34Mahmoud Alhariri: Apixaban in Hemodialysis-Treated Kidney Failure With Newly Diagnosed AF
-
May 18, 2026, 16:33Dimitrios Kontothanassis: The Role of Thermal Ablation in GSV Reflux Treatment – LIVE 2026
-
May 18, 2026, 16:32Michael Lichardi: New Publication on Complex Anticoagulation Management in Critical Care
-
May 18, 2026, 16:28Reza Shojaei: The Global Plasma-to-Ig Supply Chain